BioVenture VoiCes with Chris Garabedian Episode 33: Pappas Capital's Art Pappas
Jan 26, 2026
Art Pappas, founder and managing partner of Pappas Capital with decades in international pharma and life‑science investing. He recounts global pharma leadership and moves into early‑stage investing. Topics include building translational programs with universities, partnering with corporate LPs and co‑investors, Pappas Capital’s fund strategies and timelines, and how AI and simulation may reshape R&D.
AI Snips
Chapters
Books
Transcript
Episode notes
International Finance Informs Deal Strategy
- Managing international balance sheets taught Art to value equity, tax and local accounting in deal structuring.
- That operational finance perspective now informs how Pappas Capital evaluates acquisitions and partnerships.
Founding Pappas Capital
- After leaving GSK in 1994, Art started Pappas Capital to provide project financing and help companies enter international markets.
- Early clients included Quintiles (IQVIA) and a Canadian biotech, and that work taught them venture mechanics and LP value.
Three-Pronged Firm Model
- Pappas Capital runs three business lines: venture funds, translational programs, and specialized co-investment funds with corporates.
- Having corporates and CROs as LPs provided deal flow and operational support that improved exit outcomes.
